ライフサイエンスコーパス: year

1 pact on health status (quality-adjusted life-years).

2 control arm (median [range] age, 67 [38-82] years).

3 logically normal individuals (ages 55 to 101 years).

4 phomas (45 females, 70 males; mean age of 46 years).

5 terview was 33.20 (6.25) years (range, 16-63 years).

6 age was 58 years (interquartile range, 51-68 years).

7 rvention, of whom 231 were followed up for 1 year.

8 was cardiovascular death, MI, or stroke at 1 year.

9 from MIPD, with a threshold of 22 cases per year.

10 uld prevent approximately 107 500 deaths per year.

11 etoacidosis during the most recent treatment year.

12 advanced ovarian cancer survive more than 5 years.

13 e that life has been on land for billions of years.

14 d 1 (8%) female, with an average age of 18.2 years.

15 t cumulative effect occurring during grazing years.

16 their current address for at least another 4 years.

17 er 350M km in a global social network over 5 years.

18 tested at baseline and annually for up to 5 years.

19 men included in the analysis was 48.5 (11.1) years.

20 ed with lower risk of device infections at 5 years.

21 to manage and treat DM has emerged in recent years.

22 r over a mean follow-up period of 10.4+/-3.7 years.

23 f surgical indication, compared to PK over 5 years.

24 date of diagnosis of melanoma by at least 2 years.

25 ere white; the mean (SD) age was 69.7 (14.1) years.

26 perienced a high burden of disease in recent years.

27 se or use of asthma medication in the past 5 years.

28 t was the development of asthma until age 12 years.

29 e for resectable OS in those younger than 40 years.

30 indicate that arrest effects endured up to 5 years.

31 egulatory networks for dozens of millions of years.

32 ished in high-impact journals in the past 10 years.

33 known thus far took place over thousands of years.

34 t survival, and stable renal function over 4 years.

35 ), respectively, which was consistent across years.

36 The patients ranged in age from 19-89 years.

37 standard-of-care procedure over the past 40 years.

38 h benefits to the populations during the ten years.

39 disease and lung function at ages 12 and 18 years.

40 s important industrial process for nearly 50 years.

41 pectively, as adverse outcomes at ages 15-35 years.

42 erall incidence rate of 2.8 per 1,000 person-years.

43 care program, to usual community care over 2 years.

44 The average time of follow-up was 7.3 years.

45 gnosis before 2007 or after 2013 and age <18 years.

46 001) and clinical benefit (OR 0.95 per extra year, 0.92-0.98; p=0.004).

47 complete clinical success (OR 0.95 per extra year, 0.93-0.98; p<0.001) and clinical benefit (OR 0.95

48 women (mean age +/- standard deviation, 61.7 years +/- 13.8) were recruited from a single osteoporosi

49 n-Hispanic white, with mean age+/-SD 62+/-11 years; 16% (n=237) were cognitively impaired during hosp

50 Among 336 randomized patients (mean age, 68 years; 16% women), 333 completed the trial.

51 3 (6.6%; 95% CI: 6.3%, 6.8%) (mean age, 48.1 years +/- 18.1; range, 15-102 years) had a newly detecte

52 liance: 1) regular compliers (RC) (>/=2 PIMT/year); 2) erratic compliers (EC) (<2 PIMT/year); and 3)

53 tored in St. Croix, US Virgin Islands over 7 years (2004-2011), and validated with data from 2012 to

54 in projected ranges and threat level by the years 2061-2080, for 12 European forest tree species und

55 n per 1.73 m(2) Over a median follow-up of 8 years, 228 (6.4%) cases of incident CKD occurred in part

56 atients with AML (mean [SD] age, 59.5 [16.6] years; 23939 men and 19310 women), 11277 (26.1%) were ad

57 During a median follow-up of 6.8 years, 256 recipients died, 35 (13.7%) from recurrent ca

58 r adjusted HR, 3.12 [95% CI, 1.35-7.23]; 1-4 years, 3.29 [1.89-5.74]; and 4+ years HR, 1.15 [0.34-3.9

59 p of 5.0 years (interquartile range, 3.5-6.0 years), 38 (15%) patients died and 106 (41%) either died

60 ized participants (mean age, 50.4 [SD, 13.3] years; 42% women), 113 (83%) completed the study.

61 The mean age of participants was 69 years, 76% of participants were white, and 90% were non-

62 ed to participate in the study (mean age, 86 years; 76% female) and 359 had 840 falls in 43 months.

63 hospitalized within the first posttransplant year (78% vs 57%), all P < .001.

64 subjects (593 [52.8%] female; mean age, 67.1 years +/- 8.7 [standard deviation]) underwent FD and Ecc

65 and 992 (521 [52.5%] female; mean age, 67.1 years +/- 8.7) underwent FD and T1 measurement.

66 ease progression to recovery (median 16% per year, 95% uncertainty range 11%-21%).

67 r for sepsis than nonsepsis individuals (0-1 year adjusted HR, 3.12 [95% CI, 1.35-7.23]; 1-4 years, 3

68 in-hospital death among patients aged 18-49 years (adjusted odds ratios [aOR] = 0.21; 95% confidence

69 13 096; mean age, 42 years; age range, 15-95 years) admitted with BAPT from January 1, 2006, to Decem

70 min/1.73 m2 for at least 3 months during the year after discharge.

71 on of CHD with readmission was assessed to 7 years after delivery.

72 ot develop HGD or esophageal cancer within 5 years after index endoscopy.

73 th the de novo DSA ABMR (63% versus 34% at 8 years after rejection, respectively; P<0.001).

74 DS AND Twenty-five patients aged median 12.0 years after repair of tetralogy of Fallot and similar le

75 ompounds has begun to emerge often months to years after their initiation.

76 ting a decade later in life in the 30- to 39-year age range.

77 ods Adult patients (n = 13 096; mean age, 42 years; age range, 15-95 years) admitted with BAPT from J

78 to "blue" wavelengths was lost 300 million years ago, before the origin of modern beetles.

79 Compared with 10 and 20 years ago, current results reflect a substantially lower

80 dy cohort, the mean (SD) age was 69.6 (12.1) years among 1105356 patients (40.2% female) before publi

81 publication of the guideline and 70.0 (11.9) years among 1116472 patients (39.8% female) after public

82 initial increase in the IG during the first year and smaller decline afterward.

83 er age groups (for example, women aged 18-34 years and >/=75 years had 54% [95% confidence interval,

84 ge, and body mass index were 57.5 (+/- 10.1) years and 36.1 (+/- 6.2) kg/m(2), respectively, and 82%

85 have been commercially available for over 15 years and are providing significant value to growers.

86 changes in the numbers of deaths and in life years and life expectancy at birth, attributable to chan

87 ation-based random sample of participants 65 years and older was chosen from 6 study centers from the

88 ral population sample of 2415 people aged 40 years and over in Australia.

89 ar trends were seen in outpatients aged >/=5 years and pediatric admissions.

90 ly lose 2.3 million disability-adjusted life-years and US$3.5 billion of economic productivity every

91 RETATION: On average older men now spend 2.4 years and women 3.0 years with substantial care needs, a

92 rotating arm (median [range] age, 65 [44-87] years) and 49 patients to the control arm (median [range

93 MT/year); 2) erratic compliers (EC) (<2 PIMT/year); and 3) non-compliers (NC) (no PIMT).

94 tive if continued over 2 years rather than 1 year, and if done at the time of year when transmission

95 defined by any HF encounter during the first year, and incident HF with either 1 inpatient or 2 outpa

96 ecosystems, fix up to 27.4 Tg of carbon per year, and provide important structural components for li

97 The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis

98 odent, with a maximum life span exceeding 30 years, and found that injury responses in this species a

99 nd disability has leveled off in more recent years, and is even improving for some measures.

100 ated the field of hepatology for the past 25 years, and its cure in the majority of treated patients

101 55.2 to 60.0) will be obese at the age of 35 years, and roughly half of the projected prevalence will

102 [range, 1-25 years] vs 10 years [range, 2-26 years]), and mean body mass index (31.4 kg/m(2) [range,

103 aOR = 0.48; 95% CI, 0.24 to 0.97), and >/=65 years (aOR = 0.39; 95% CI, 0.17 to 0.66).

104 nfidence interval [CI], 0.05 to 0.97), 50-64 years (aOR = 0.48; 95% CI, 0.24 to 0.97), and >/=65 year

105 proximately <40 years old), midcareer (15-24 years, approximately 40-50 years old), and senior surgeo

106 40-50 years old), and senior surgeons (25-35 years, approximately 50-60 years old).

107 ch facility referred for transplant within 1 year as the primary outcome, and disparity in the referr

108 edically eligible and willing to donate each year at the time of imminent death.

109 ble BCR-ABL1 transcripts for the 2 preceding years at least were eligible for inclusion.

110 ulation comprised 76,188 subjects aged 16-89 years at recruitment.

111 of water and THF (SmI2(H2O)n) has in recent years become a versatile and useful reagent, mainly for

112 a decrease in transmission that occurred 10 years before 2013.

113 g novel therapies to this patient population years before PFS results are mature.

114 ard clinicopathologic prognostic factors (10-year biochemical recurrence-free survival [bRFS], 29%; d

115 69%), followed by basal prostate cancers (10-year bRFS, 39%; DMFS, 73%; PCSS, 86%; OS, 80%) and lumin

116 OS, 80%) and luminal A prostate cancers (10-year bRFS, 41%; DMFS, 73%; PCSS, 89%; OS, 82%).

117 nnins have been proposed in the last fifteen years, but are generally time consuming and require the

118 s of similar age, sex, and low Framingham 10-year coronary artery disease risk scores with an echocar

119 men and 5 women; mean [SD] age, 76.4 [12.2] years) detected increased PD-1 and PD-L2 expression in h

120 baseline to 80% (943 of 1184 patients) at 1 year (difference 12%), whereas in the control group it i

121 baseline to 67% (732 of 1092 patients) at 1 year (difference 3%).

122 n (ISCO) has gained more attention in recent years due to the generation of highly reactive and selec

123 ak industrial activity that occurred 5 to 10 years earlier.

124 at any detectable level who had excellent 5-year EFS (98.1%) and OS (100%).

125 of deep sequencing techniques in the recent years, enhancers have been systematically identified in

126 Ten-year ESRD-free survival rates were 43%, 94%, and 72% in

127 Over the 15 years, EVI decreased significantly in Jamaica, Haiti, Do

128 The 10-year FFBF rate was 72% in the hypofractionation group an

129 ists with different levels of expertise (1-9 years) first reviewed only a fraction of the full multip

130 ment), which were maintained at the end of 1 year follow-up in these five patients.

131 The 5-year follow-up of the TWENTE participants was prespecifi

132 SEER tumor registries and who completed a 15-year follow-up survey.

133 26.2 years for HIV-infected infants and 61.4 years for all HIV-exposed infants; clinical outcomes for

134 Mean (SD) patient age was 62.1 (20.3) years for ambulatory vs 48.1 (22.3) years for diplopia-r

135 1 (20.3) years for ambulatory vs 48.1 (22.3) years for diplopia-related ED visits.

136 t and with confirmatory testing, LE was 26.2 years for HIV-infected infants and 61.4 years for all HI

137 (SD) age at end of follow-up was 4.6 (0.40) years for the 61359 children included in the study.

138 Among individuals aged 18 to 34 years, frequent indoor tanners (>/=10 times in the past

139 mortality were similar for early-career (<15 years from medical school, approximately <40 years old),

140 h isolated focal dystonia evaluated within 5 years from symptom onset, enrolled in the Natural Histor

141 eness ratios (cost per quality-adjusted life year gained) from the societal perspective across a rang

142 roke) deaths prevented or postponed and life-years gained (LYGs) over the study period, stratified by

143 mation on the long-term benefits (e.g., life-years gained and mortality reduction) and harms (e.g., o

144 Nonetheless, in recent years, genetic manipulation tools have been successfully

145 Stimulation of cumulative 6-year GPP by warming (29%, P = 0.02) and eCO2 (26%, P = 0

146 This subgroup, when compared with the <5 year group, experienced similar rates of cyst growth (19

147 or example, women aged 18-34 years and >/=75 years had 54% [95% confidence interval, 42% to 67%] and

148 mean age, 48.1 years +/- 18.1; range, 15-102 years) had a newly detected finding of ovarian cyst desc

149 Advances over the past 10 years have allowed large-scale assessment of one epigene

150 Recent years have seen much progress in theory and method devel

151 ith improved global longitudinal strain at 1 year (hazard ratio=0.29; P<0.001).

152 In nonhuman primates, a 2-year high-fat, high-sucrose diet increased hepatic mIndy

153 5-7.23]; 1-4 years, 3.29 [1.89-5.74]; and 4+ years HR, 1.15 [0.34-3.94]).

154 hs [0.025% per year] v 94 deaths [0.038% per year]; HR, 0.65; 95% CI, 0.45 to 0.94; P = .02) by the d

155 survival rate was 96.1% (95.8-96.4), and 20-year implant survival rate was 89.7% (87.5-91.5).

156 For total knee replacement, 10-year implant survival rate was 96.1% (95.8-96.4), and 20

157 and multi-site cohorts, and increased over 1 year in Parkinson's disease but not in controls at a sin

158 es and 118,095 comparable controls aged > 65 years in 2009 using Medicare claims data.

159 chronosequence spanning over more than 5000 years in boreal forest in northern Sweden that belowgrou

160 Patients in both cohorts were adults (>/=18 years in England, >/=16 years in Scotland), were diagnos

161 andardised mortality ratio in men aged 20-69 years in fast vs slow privatised towns: 1.13, SMR 0.83,

162 s were adults (>/=18 years in England, >/=16 years in Scotland), were diagnosed with paracetamol over

163 rable progress has been made during the last years in understanding the SnRK1 signaling pathway, many

164 e than 500 mosquito generations (or about 40 years) in 24% of runs, while in those runs where resista

165 average of 6.5 +/- 3.4 years (range: 1 to 13 years) in function.

166 In the past several years, inflammasome activation and subsequent signal tra

167 During a median follow-up of 5.0 years (interquartile range, 3.5-6.0 years), 38 (15%) pat

168 551 (63.9%) were male and median age was 58 years (interquartile range, 51-68 years).

169 In these patients, median age was 58 years (IQR 51-62), median number of previous lines of th

170 rgest increase was among older patients (>75 years; n = 4441) who experienced an increase from 55.1 p

171 by their number of exacerbations in the past year: none, few (one to two), or exacerbation prone (>/=

172 t, early pregnancy body mass index, smoking, year of delivery, maternal pregestational diabetes, hype

173 m(2) , rising dramatically during the fourth year of drought.

174 ring of chow-fed dams throughout their first year of life, an effect not present in the offspring fro

175 s, with normalization of weight in the first year of life.

176 s at 5 years of 8.1% (3.4 to 12.8) and at 10 years of 3.9% (-0.6 to 8.4).

177 , 0.74-0.92), with absolute differences at 5 years of 8.1% (3.4 to 12.8) and at 10 years of 3.9% (-0.

178 We assessed 152 masters athletes 54.4+/-8.5 years of age (70% male) and 92 controls of similar age,

179 syndrome (CIS) with disease onset before 18 years of age and duration of less than 4 years were incl

180 al cohort of employed men and women 18 to 74 years of age at baseline examination in 1967 to 1973.

181 eine had improved respiratory function at 11 years of age compared with children treated with placebo

182 Mullen scores at 2 years of age differed significantly between clusters.

183 Among women 45 to 64 years of age in ARIC and REGARDS, age-adjusted hazard ra

184 the newborn period and in lung function at 8 years of age in children whose birth was extremely prema

185 A total of 113 participants older than 50 years of age with a range of AMD severity.

186 wo hundred seventy-eight women from 25 to 76 years of age with increased breast cancer risk who under

187 cans (N = 51 males, mean +/- SD 24.1 +/- 3.1 years of age) showed similar sulci patterns, which allow

188 ificantly according to age (among donors <70 years of age), sex, or height (among donors </=190 cm ta

189 ease in monthly MIT at <15, 15-64, and >/=65 years of age, respectively, while the average increase i

190 ividuals ranging from less than 1 year to 93 years of age.

191 Plants have undergone 470 million years of evolution on land and different groups have dis

192 During 1,190,170 person-years of follow-up (1982-2012), there was no association

193 d 95% CIs of diabetes risk.In 494,741 person-years of follow-up, 5207 participants developed T2DM.

194 (P=0.004), respectively, over a total of 20 years of follow-up.

195 s, or IBD-unclassified with 24,543.0 patient-years of follow-up.

196 diagnosed eczema/skin allergy in the first 6 years of life, adjusting for confounders.

197 come Measures: HIV transmissions and deaths, years of life, and budgetary outlays (2015 U.S. dollars)

198 more gradually increased during the first 4 years of life.

199 ipants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident infections

200 in survival was observed for increasing pack-years of smoking ( Ptrend = .008), with HR for death of

201 of 1.49 (95% CI, 1.05 to 2.10) for > 60 pack-years of smoking versus never smoking.

202 lotinib who stopped therapy after at least 3 years of TKI treatment and in molecular response 4.5 (MR

203 mulative risk exposure between ages 6 and 24 years) of systolic BP, total-cholesterol, and smoking as

204 ischaemic strokes, 369 occurred at age >/=80 years, of which 124 (33.6%) were in non-anticoagulated p

205 With the exception of the oldest subject (15 years old at enrollment), all subjects remained off ERT

206 Patients were 17 years old or younger and had Crohn's disease, ulcerative

207 ses compared to age-matched TD controls (<18 years old) and (b) decreases in the amygdala as people w

208 midcareer (15-24 years, approximately 40-50 years old), and senior surgeons (25-35 years, approximat

209 years from medical school, approximately <40 years old), midcareer (15-24 years, approximately 40-50

210 r surgeons (25-35 years, approximately 50-60 years old).

211 n per 1.73 m(2) At baseline, mean age was 55 years old, 37% of participants were men, and mean eGFR w

212 tates, African American parents and their 11-year-old children were assigned randomly to the Strong A

213 History A 63-year-old man with learning difficulties presented to the

214 14)N) values from approximately 2.31-billion-year-old shales of the Rooihoogte and Timeball Hill form

215 For many years, only a small fraction of the human genome was bel

216 Children's Research Hospital who survived 10 years or longer from initial diagnosis and were 18 years

217 re or moderate to severe) for adults aged 60 years or older (n = 16,770) over 3 time periods in the N

218 or longer from initial diagnosis and were 18 years or older as of June 30, 2015.

219 Conclusion With an 83% 8-year OS rate, long-term follow-up of the FOLL05 trial co

220 Five-year OS was 86.8% and 78.8% for patients treated at GR a

221 hange for these patients was -0.12+/-0.51 dB/year over a mean follow-up period of 10.4+/-3.7 years.

222 Still, 5-year overall survival (89% +/- 3% vs 90% +/- 4%; Plog-ra

223 00000 person-years to 99.7 per 100000 person-years (P < .001 for trend).

224 pression ex vivo decreased from age 4.5 to 6 years (P(U,LPS) < 0.001; P(PI) = 0.051; P(FOXP3) < 0.001

225 43 years with a mean (+/-SD) of 28.0+/-5.079 years (p=0.746).

226 nd (18)F-FDOPA uptake (in caudate: age </=50 years, p=0.0002; all other age ranges, p<0.0001; in puta

227 y outcomes of the model were changes in life-years per 100 000 total population over 40 years (to 205

228 During a 3-year period between December 7, 2009, and November 7, 20

229 mission where IRS was discontinued after a 4-year period followed by universal LLIN distribution.

230 paediatric MRI sedations performed over a 5-year period using records of patients' biodata, MRI date

231 20 British breeding bird species across a 40-year period.

232 We followed participants for 35353 person-years (PY).

233 2015 U.S. dollars per quality-adjusted life year (QALY) gained and number of fragility fractures.

234 al 12 662-132 452) per quality-adjusted life-year (QALY) gained, pound372 207 (268 162-1 903 385) per

235 increases in survival, quality-adjusted life years (QALYs), costs, and resulting budget impact betwee

236 In univariate analysis, age >60 years, radiation dose, bilateral ocular involvement at p

237 sion in 1st-, 2nd-, 3rd-, 4th-, 6th-, or 8th-year radiographic findings compared with baseline).

238 at the antenatal interview was 33.20 (6.25) years (range, 16-63 years).

239 156 implants with an average of 6.5 +/- 3.4 years (range: 1 to 13 years) in function.

240 respectively), mean duration of diabetes (10 years [range, 1-25 years] vs 10 years [range, 2-26 years

241 diabetes (10 years [range, 1-25 years] vs 10 years [range, 2-26 years]), and mean body mass index (31

242 diabetic patients without DPN, mean age (60 years [range, 38-79 years] vs 61 years [range, 46-75 yea

243 ean age (60 years [range, 38-79 years] vs 61 years [range, 46-75 years], respectively), mean duration

244 ted to be more effective if continued over 2 years rather than 1 year, and if done at the time of yea

245 Risks of disease-related outcomes and 5-year recurrence-free, disease-specific, and overall surv

246 generally long (10s to 100s of thousands of years) relative to conventional paleoseismic records det

247 ange, 38-79 years] vs 61 years [range, 46-75 years], respectively), mean duration of diabetes (10 yea

248 ealth status, and AF treatment, as well as 2-year risk of death, hospitalization, thromboembolic even

249 ent in pediatric patients with T1D after one-year's poor glycemic control.

250 738 886 participants with a mean age of 55.6 years (SD 9.7), 59.5% of whom were women.

251 valvular atrial fibrillation (mean age, 74.7 years [SD, 10.8]; men, 55.8%; NOAC dabigatran, 45347 pat

252 In recent years, several network models have been introduced to el

253 In recent years, significant progress has been made in the underst

254 Over an 8-year study period, a total of 1283 pregnancies in 1208 w

255 s missed more than two appointments in the 3 year study period.

256 After 3 years, surgery led to a gain of 0.199 QALYs compared wit

257 trial, off-pump CABG led to lower rates of 5-year survival and event-free survival than on-pump CABG.

258 as a human pathogen for tens of thousands of years thanks to its ability to resist and adapt to the a

259 Technologies have emerged in recent years that make it possible to track the masses of singl

260 is well tolerated in children as young as 6 years, that children show intact fear and extinction lea

261 el disease unclassified before the age of 10 years, the disease is complex, multifactorial, and lifel

262 During a mean follow-up of 3.9+/-2.4 years, the primary end point of death, transplant, or ad

263 In recent years, there has been a huge rise in the number of publi

264 Over a 40 year time horizon, incremental cost-effectiveness ratios

265 from 78 individuals ranging from less than 1 year to 93 years of age.

266 nced an increase from 55.1 per 100000 person-years to 99.7 per 100000 person-years (P < .001 for tren

267 significant progress has been made in recent years to decipher various molecular aspects of the regul

268 e-years per 100 000 total population over 40 years (to 2050).

269 ons over the past decade; however, given the year-to-year variability in support to dental institutio

270 Each year, two or three species that had been considered to b

271 Rates of 1-year unplanned rehospitalization were highest among blac

272 significantly reduced (40 deaths [0.025% per year] v 94 deaths [0.038% per year]; HR, 0.65; 95% CI, 0

273 the past decade; however, given the year-to-year variability in support to dental institutions, it i

274 duration of diabetes (10 years [range, 1-25 years] vs 10 years [range, 2-26 years]), and mean body m

275 ithout DPN, mean age (60 years [range, 38-79 years] vs 61 years [range, 46-75 years], respectively),

276 The CI of nonrelapse mortality after 1 year was 17% (95% CI, 8% to 26%) after RIC and 25% (95%

277 iciency, gastric acid inhibitor use for >/=2 years was associated with an increased subsequent risk o

278 Eligible participants were aged 6-11 years, weighed 25 kg or more, had virological suppressio

279 e probabilities of HCC recurrence at 1 and 5 years were 5.7% and 12.8%, respectively.

280 % confidence intervals (CI) per 1,000 person-years were as follows: non-biologic, 14.2 (11.5-17.4); e

281 18 years of age and duration of less than 4 years were included in this study.

282 ty-seven eyes with a median follow-up of 2.6 years were included.

283 IRs among patients aged 0-4 years were more than double overall IRs.

284 l-group trial, 401 participants aged 6 to 11 years were randomized to receive once-daily tiotropium 5

285 uent indoor tanners (>/=10 times in the past year) were more likely to report never/rare use of prote

286 n = 40058; range, 142-16608; mean age, 53-79 years) were included.

287 ther than 1 year, and if done at the time of year when transmission is lowest.

288 Methods We evaluated men who were age </= 75 years when diagnosed with localized prostate cancer betw

289 Naive lymphocyte counts peaked around 1 year, whereas most memory lymphocyte subsets more gradua

290 S$3.5 billion of economic productivity every year, which is comparable to recent acute epidemics, inc

291 45 years with a mean (+/-SD) of 27.6+/-7.607 years, while that of the controls was 21-43 years with a

292 e invited individuals aged between 35 and 70 years who intended to live at their current address for

293 lance mammography use among women age >/= 65 years who reported a history of breast cancer.

294 We enrolled adult patients (aged >/=18 years) who had cytologically or histologically confirmed

295 The age range of the patients was 18-45 years with a mean (+/-SD) of 27.6+/-7.607 years, while t

296 years, while that of the controls was 21-43 years with a mean (+/-SD) of 28.0+/-5.079 years (p=0.746

297 older men now spend 2.4 years and women 3.0 years with substantial care needs, and most will live in

298 outes also fluctuates over the course of the year, with increased travel from rural to urban communit

299 thousands of patients with nAMD treated each year worldwide.

300 ver 60 million MRI procedures performed each year worldwide.